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4,5-dihydro-1H-pyrazole-1-carbothioamides were synthesized by reﬂuxing selected chalcones and
thiosemicarbazide in alkaline medium. Similarly N-3,5-trisubstituted-4,5-dihydro-1H-pyrazole-1-
carboxamides were synthesized by reﬂuxing selected chalcones with N-(4-chlorophenyl)semicarbaz-
ide in alkaline medium. Structures of the synthesized compounds were conﬁrmed by elemental anal-
ysis and spectral (UV, IR, 1H NMR, 13C NMR, and mass) data, which were in line with the
proposed structures.
All compounds were tested for their anticonvulsant activity using pentylenetetrazole induced sei-
zure (PTZ) and maximal electroshock seizure (MES) tests in mice at a dose level of 50 mg/kg.
Among the 2-pyrazoline-1-carbothioamide derivatives, 5-(2,6-dichlorophenyl)-3-(thiophen-2-yl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide (2e) reduced grade-5 seizure activity and also increased
survival rate in PTZ test. In MES test, 5-(4-methoxyphenyl)-3-[4-(methylsulphonyl)phenyl]-4,5-
dihydro-1H-pyrazole-1-carbothioamide(2g) has not only decreased seizure severity, but also
increased survival rate. Among the 2-pyrazoline-1-carboxamide derivatives, 3-(5-bromothiophen-
2-yl)-N-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (3d)armara University Faculty of
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Scheme 1 Synthetic protocol of 1a–i, 2a–i and 3a–e.1. Introduction
Epilepsy is a central nervous system disorder characterized by
unprovoked, recurrent seizures thatmay affect physical, mental,
or behavioral functioning (Trimble and Dodson, 1994). Not
only its medical inﬂuence, but also extensive psychological
and economic outcomes reduce epilepsy patients’ quality of life.
Successful seizure control is the key parameter in decreasing the
psychosocial and economic costs of this disorder (Honarmand
et al., 2011). The clinical need of refractory epilepsy remains un-
met and drugs in use are not effective enough in epilepsy. Older
antiepileptic drugs (AEDs), which have advantages like lower
cost, wide availability and long-term experience are still in use
today, but have a greater risk of serious toxicity compared to
newgenerationAEDs,which differ in terms ofmechanismof ac-
tion and pharmacokinetic properties, and are also better toler-
ated (Eddy et al., 2011). Therefore researchers in medicinal
chemistry are still proceeding to study on potential compounds
(Stefan and Feuerstein, 2007; Siddiqui and Ahsan, 2010; Guan
et al., 2010).References and further reading may be available
for this article. To view references and further reading you must
purchase this article. Among these compounds, 2-pyrazoline is a
promising structure as a anticonvulsant agent (Ku¨c¸u¨kgu¨zel
et al., 2000; O¨zdemir et al., 2007a,b). N–CO moiety is well rec-
ognized as pharmacophoric requirements in some of the well-
known anticonvulsant agents with varied mechanisms of action
(Nikhil and Kishore, 2010).
During the past 20 years, the following ﬁfteen new AEDs
have been approved: eslicarbazepine acetate, felbamate, gaba-
pentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine,
pregabalin, retigabine, ruﬁnamide, stiripentol, tiagabine, topi-
ramate, vigabatrin, and zonisamide (Bialer, 2012). These new
generation AEDs also affect some common mechanisms which
are underlying causes of other CNS disorders. Therefore, fu-
ture design of new AEDs may also have therapeutic potential
in non-epileptic CNS disorders, such as neuropathic pain, mi-
graine prophylaxis and bipolar disorder or ﬁbromyalgia. This
piquant ﬁnancial situation attracts pharmaceutical industry a
lot.
Recently, our group has been investigating the possible
pharmacological potential of new molecules that contain a
pyrazole scaffold (Koc¸yig˘it-Kaymakc¸ıog˘lu et al., 2005, 2011).
Among these series N-ethyl-N0-(3,5-dimethylpyrazole-4-
yl)thiourea and N-(2-ethoxyphenyl)-N0-(3,5-dimethylpyra-
zole-4-yl)urea were found to show better anticonvulsant activ-
ity in MES test. In the MES test, these compounds exhibited
median effective doses (ED50) of 17.14 and 17.46 mg/kg,
respectively. In view of these results and as a part of our endur-
ing studies in the area of anticonvulsant agents, it was con-
ceived to combine two pharmacophoric groups: pyrazoline
ring and N–CO moiety. Pyrazoles and their reduced forms,
pyrazolines, are well known nitrogen containing heterocylicBeyhan, N. et al., Synthesis an
mistry (2013), http://dx.doi.orgcompounds and various methods have been reported for their
synthesis (Abid et al., 2009). In the present study, as starting
compounds, a series of chalcones were prepared via Claisen
Schmidt condensation and 2-pyrazoline derivatives 2a–i and
3a–e were synthesized by the reaction of chalcones with thio-
semicarbazide and N-(4-chlorophenyl)semicarbazide. 2-Pyraz-
olines were tested for their potential anticonvulsant activity in
pentylenetetrazole induced seizure (PTZ) and maximal electro-
shock seizure (MES) tests.
2. Results and discussion
2.1. Chemistry
The synthetic route to the target compounds is outlined in
Scheme 1. The intermediated chalcones (1a–i) were prepared
by reacting equimolar aldehyde and ketone in the presence of
a base by conventional Claisen-Schmidt condensation. 3,5-
disubstituted-4,5-dihydro-1H-pyrazole-1-carbothioamides (2a–i)
were synthesized by reﬂuxing compounds1a–i and thiosemicar-
bazide in the presence of alkaline medium and similiarly, N,3,5-
trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides (3a–e)
were synthesized by reﬂuxing selected chalcones withN-(4-chlo-
rophenyl)semicarbazide in alkaline medium. The chalcone
derivatives 1a, 1c, and 1d were original compounds. The chal-
cone derivatives 1b, 1e and 2-pyrazoline derivative2g have
CAS numbers in SciFinder Scholar, but our study, for the ﬁrst
time, determined their structures.d anticonvulsant activity of some 2-pyrazolines derived from
/10.1016/j.arabjc.2013.07.037
Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones 3All the compounds were isolated in satisfactory yields (35–
91%) and puriﬁed by recrystallization from ethanol. The pur-
ity of the compounds was established by thin layer chromatog-
raphy (TLC) and elemental analysis.
Structures of the novel synthesized compounds were con-
ﬁrmed by elemental analysis and spectral (UV, IR, 1H
NMR, 13C NMR, and mass) data, which were in line with
the proposed structures.
The IR spectra of the compounds 2a–i afforded pyrazoline
C‚N stretching (1589–1573 cm1), thiocarbamoyl group N–
H stretching (3462–3232 cm1) and C‚S stretching (1373–
1348 cm1) bands. The CH2 protons of the pyrazoline ring res-
onated as a pair of doublets of doublets at 3.10–3.22 ppm
(HA), 3.86–4.00 ppm (HB). The CH (HX) proton appeared as
a doublet of doublets at 5.84–6.32 ppm due to vicinal coupling
with the two magnetically non-equivalent protons of the meth-
ylene group at position 4 of the pyrazoline ring (JAB: 17.65–
18.40 Hz, JAX: 2.90–8.01 Hz, JBX: 11.07–13.28 Hz). The same
protons for compounds 3a–e were resonated as a pair of dou-
blets of doublets at 3.13–3.22 ppm (HA), 3.84–3.98 ppm (HB).
Also the CH (HX) proton appeared as a doublet of doublets at
5.43–6.42 ppm (JAB = 17.76–18.40, JAX = 5.05–5.50 Hz,
JBX = 11.78-13.02 Hz). N–H protons of the thiocarbamoyl
group for compounds 2a–i were seen at 7.41–8.08 and 7.90–
8.16 ppm as two singlets. N–H protons of the carboxamide
group for compounds 3a–e were seen at 9.10–9.37 ppm as sin-
glet. The protons belonging to the aromatic ring and the other
aliphatic groups are observed with the expected chemical shiftTable 2 Anticonvulsant properties of compounds 3d and 3e in PTZ
Parameter Onset time (min) Grade 1% Grade 2%
PTZ 1.20 99*** 80***
3d 2.10 67*** 38***
3e 2.58 64*** 42***
Each group consists of 6–10 mice. Compounds were compared to contro
*** p< 0.001.
Table 1 Anticonvulsant activity results of compounds 2a–i and 3a–
Comp. Ar1 Ar2
2a 4-Triﬂuoromethyl 4-Methoxyphenyl
2b 5-Chlorothiophen-2-yl 2,6-Dichlorophenyl
2c 5-Bromothiophen-2-yl 2,6-Dichlorophenyl
2d 4-Methylsulfonylphenyl 2,6-Dichlorophenyl
2e Thiophen-2-yl 2,6-Dichlorophenyl
2f Phenyl 2,6-Dichlorophenyl
2 g 4-Methylsulfonylphenyl 4-Metoxyphenyl
2 h Thiophen-2yl 3,4-Dimetoxyphenyl
2i Thiophen-2yl 4-Dimethylaminophenyl
3a Phenyl 2,6-Dichlorophenyl
3b 4- Methylsulfonylphenyl 2,6-Dichlorophenyl
3c Thiophen-2-yl 2,6-Dichlorophenyl
3d 5-Bromothiophen-2-yl 2,6-Dichlorophenyl
3e 5-Chlorothiophen-2-yl 2,6-Dichlorophenyl
Control
Each group consists of 6–10 mice. Compounds were compared to contro
*** p< 0.001.
Please cite this article in press as: Beyhan, N. et al., Synthesis an
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showed a [MH]+ peak, in line with their molecular formula.
2.2. Pharmacology
The anticonvulsant activity of the new compounds was deter-
mined by using PTZ (Sigma) and MES tests. The use of intact
rodents, makes it easier to detect possible anticonvulsant effect
regardless of the mechanisms of action. MES and PTZ tests
can be used in high throughput screening, as shown by the Na-
tional Institutes of Health Anticonvulsant Screening Program.
Furthermore, these models can provide insight into pharmaco-
kinetic–pharmacodynamic relations.
All compounds were suspended in 0.5% methyl cellulose
and administered intraperitoneally at a dose of 50 mg/kg
30 min prior the tests. The anticonvulsant potential of these
compounds was investigated by both PTZ and MES tests
and results are shown in Table 1. None of the compounds
tested showed anticonvulsant effect in the MES test. The
PTZ model basically simulates petit mal seizures. Among the
2-pyrazoline-1-carbothioamide derivatives, compound 2e car-
rying thiophen and 2,6-dichlorophenyl ring in 2-pyrazoline
moiety decreased grade-5 seizures and also increased survival
rate in PTZ test. Compound 2c having 5-bromothiophen and
2,6-dichlorophenyl ring in 2-pyrazoline moiety increased sur-
vival rate in PTZ test. In MES test, compound 2g having 4-
methylsulfonylphenyl and 4-methoxyphenyl group in 2-pyraz-
oline moiety not only decreased seizures but also increasedtest.
Grade 3 % Grade 4 % Grade 5% Survival %
75*** 71*** 52*** 50***
30*** 18*** 10*** 100***
35*** 21*** 10*** 95***
l group and statistical signiﬁcance.
e.
Dose, mg/kg PTZ test (%) MES test (%)
Grade 5 Survival Seizure Survival
50 72*** 38*** 80*** 10***
50 70*** 63*** 98*** 12***
50 75*** 75*** 75*** 10***
50 81*** 28*** 82*** 10***
50 41*** 48*** 50*** 60***
50 44*** 52*** 50*** 60***
50 52*** 50*** 23*** 73***
50 55*** 47*** 82*** 25***
50 42*** 48*** 54*** 60***
50 80*** 22*** 70*** 38***
50 74*** 46*** 62*** 55***
50 40*** 50*** 60*** 60***
50 10*** 100*** 47*** 50***
50 10*** 95*** 52*** 55***
0 58*** 52*** 54*** 69***
l group and statistical signiﬁcance.
d anticonvulsant activity of some 2-pyrazolines derived from
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compound in MES test.
Among the 2-pyrazoline-1-carboxamide derivatives, com-
pound 3d having 5-bromothiophen and 2,6-dichlorophenyl
moiety and compound 3e having 5-chlorothiophen and 2,6-
dichlorophenyl moiety were found much more potent in PTZ
test because of the bulk and lipophilicity. The compounds 3d
and3e reduced convulsion frequency in all types of grades
(from grade 1–5). In other words, it can be said that, they in-
creased the convulsive threshold. They also prolonged onset
time from 1.20 to 2.10. and 1.20 to 3.58 s. and increased sur-
vival rate nearly by twofold from 50% to 95% and 50% to
100%, respectively (Table 2). Therefore, compounds 3d and3e
have anticonvulsant drug potential to treat petit mal seizures.
3. Conclusion
The anticonvulsant drug design was based on the presumption
(Pandeya et al., 1998) that the activity in maximal electroshock
(MES) evaluation requires at least one phenyl or similar aro-
matic group in close proximity to two electron donor atoms
and the activity in the pentylenetetrazole (PTZ) evaluation re-
quires an alkyl group substituted close to two electron donor
atoms. It has been hypothesized that, ureas and thioureas dis-
playing anticonvulsant activity interact at locations on the
putative binding site designated as aryl binding site, a hydro-
gen bonding domain and an auxiliary aryl or other hydropho-
bic binding site (Dimmock et al., 2000). Carboxamide
derivatives (3a–e) were found to be more potent than carbo-
tioamide derivatives due to their ability to form strong hydro-
gen bonds and their hydrophobic nature. Furthermore, the
carboxamide derivatives of 3d and 3e were much more potent
(90% protection) than the other carboxamides in PTZ test be-
cause of the bulk they own and their lipophilicity.
In conclusion, a series of 2-pyrazoline derivatives have been
synthesized and screened for their anticonvulsant activity. The
anticonvulsant screening indicated that among the tested com-
pounds, 2-pyrazoline-1-carboxamide derivatives carrying 5-
bromothiophen, 5-chlorothiophen and 2,6-dichlorophenyl
groups exhibited noteworthy activity in PTZ test. These data
may be useful for future molecular modiﬁcations leading to
compounds with greater favorable pharmacological
properties.
4. Experimental
4.1. Materials and methods
Chemicals were procured from Aldrich Chemical Co. The
reactions were monitored on Merck pre-coated aluminum
TLC plates 60F-254 and the products were visualized by
UV-light using chloroform and methanol as solvent system.
Melting points were determined on a Kleinﬁeld SMP II appa-
ratus and are uncorrected. The IR spectra were recorded on a
Schimadzu FTIR 8400S spectrometry. 1H NMR spectra were
recorded on Bruker (400 MHz) spectrometer instruments, in
DMSO. Chemical shifts were recorded in parts per million
downﬁeld from tetramethylsilane. The splitting patterns of
1H NMR were designed as follows: s: singlet, bs: broad singlet,
d: doublet, t: triplet, q: quartet, m: multiplet. The mass spec-
trometry was recorded on LC-MS-Agilent 1100 series in thePlease cite this article in press as: Beyhan, N. et al., Synthesis an
chalcones. Arabian Journal of Chemistry (2013), http://dx.doi.orgelectrospray mode. Elemental analysis was performed on Leco
CHNS-932 analyzer.
4.2. General procedure for the preparation of chalcones 1a–i
5 mmol substituted aldehyde and 5 mmol substituted/nonsub-
stituted ketone were dissolved in methanol (15 ml). To that
mixture, 50% (w/v) NaOH (3 ml) was added and the reaction
mixture was stirred for about 16 h at room temperature. The
progress of the reaction was monitored by TLC. After comple-
tion of the reaction, the reaction mixture was poured into ice
and the precipitate was ﬁltered, dried and crystallized from
suitable solvent (If the precipitate has not been obtained, the
reaction mixture was neutralized with 1 N HCI).
4.2.1. 3-(4-Methoxyphenyl)-1-[4-(triﬂuoromethyl)phenyl]prop-
2-ene-1-one 1a
C17H13F3O2 (M.W.: 306.279), Yield 78%, mp 112–114 C
(EtOH), UV (EtOH), kmax (loge: 205 (4.40), 248 (4.29), 350
(4.38), IR cm1. (cm1): 3010, 2939, 2843 (CH), 1658
(C = O), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.52 (3H, 2s, OCH3), 6.54 (1H, d, J= 8.64 Hz,
COCH= CH), 6.65 (1H, d, J= 8.64 Hz, COCH= CH),
7.15-7.80 (8H, m, Ar–H), Elemental Analysis: Found, %: C
66.02; H 4.22, Calculated, %: C 66.67; H 4.28.
4.2.2. 1-(5-Chlorothiophen-2-yl)-3-(2,6-dichlorophenyl)prop-2-
ene-1-one 1b
C13H7Cl3OS (M.W.: 317.618 g/mol), Yield 89%, mp 128–
129 C (EtOH), UV (EtOH), kmax (loge: 207 (4.34), 239 (4.10),
319 (4.15), IR cm1 (cm1): 3105 (CH), 1649 (C‚O), 1H
NMR (400 MHz, DMSO-d6/TMS), d, ppm (J, Hz): 7.41 (1H,
d, J= 4.13 Hz, thiophen H3); 7.48 (1H, dd, J1 = 7.65 Hz,,
J2 = 7.63 Hz 2,6-dichlorophenyl H4); 7.60-7.73 (4H, m,
COCH‚CH ve 2,6-dichlorophenyl H3, H5); 8.13 (1H, d,
J= 4.16 Hz, thiophen H4), Elemental Analysis: Found, %: C
48.96; H 2.29; S 10.00, Calculated, %: C 49.16; H 2.22; S 10.10.
4.2.3. 1-(5-Bromothiophen-2-yl)-3-(2,6-dichlorophenyl)prop-2-
ene-1-one 1c
C13H7BrCl2OS (M.W.: 362.069), Yield 89%, mp 125–126 C
(EtOH), UV (EtOH), kmax (loge): 209 (3.98), 238 (4.10), 323
(4.20), IR cm1 (cm1): 3113 (C-H), 1647 (C‚O), 1H NMR
(400 MHz, DMSO-d6/TMS), d, ppm (J, Hz): 7.45 (1H, d,
J= 8.39 Hz, 2,6-dichlorophenyl H4); 7.49 (1H, d,
J= 4.21 Hz, thiophen H3); 7.60–7.73 (4H, m, COCH‚CH
ve 2,6-dichlorophenyl H3, H5); 8.06 (1H, d, J= 4.10 Hz, thio-
phen H4), Elemental Analysis: Found, %: C 42.97; H 2.09; S
8.68, Calculated, %: C 43.12; H 1.95; S 8.86.
4.2.4. 3-(2,6-Dichlorophenyl)-1-[4-(methylsulphonyl)phenyl]prop-
2-ene-1-one1d
C16H12Cl2O3S (M.W.: 355.235), Yield 90%, mp 191–193 C
(EtOH), UV (EtOH), kmax (loge): 206 (4.25), 248 (4.12), 294
(4.20). IR cm1 (cm1): 3066, 2931 (CH), 1670 (C‚O),
1296, 1145 (SO2),
1H NMR (400 MHz, DMSO-d6/TMS), d,
ppm (J, Hz): 3.28 (3H, s, –SO2CH3); 7.44 (1H, d,
J= 8.05 Hz, 2,6-dichlorophenyl H4); 7.60–7.85 (4H, m,
COCH‚CH ve 2,6-dichloro phenyl H3, H5); 8.13 (2H, d,
J= 8.28 Hz, 4-methylsulphonylphenyl H2, H6); 8.28 (2H, d,d anticonvulsant activity of some 2-pyrazolines derived from
/10.1016/j.arabjc.2013.07.037
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Analysis: Found, %: C 52.97; H 3.53; S 8.79, Calculated, %:
C 54.10; H 3.40; S 9.03.
4.2.5. 3-(2,6-Dichlorophenyl)-1-(thiophen-2-yl)prop-2-ene-1-
one 1e
C13H8Cl2OS (M.W.: 283.173), Yield 91%, mp 93–94 C
(EtOH), UV (EtOH), kmax (loge): 206 (4.10), 244 (4.20), 311
(4.00), IR cm1 (cm1): 3086, 3072 (CH), 1653 (C‚O), 1H
NMR (400 MHz, DMSO-d6/TMS), d, ppm (J, Hz): 7.31
(1H, dd, J1 = 4.00 Hz, J2 = 4.00 Hz, thiophen H3); 7.45
(1H, dd, J1 = 8.00 Hz, J2 = 8.00 Hz 2,6-dichlorophenyl H4);
7.58-7.80 (4H, m, COCH‚CH ve 2,6-dichlorophenyl H3,
H5); 8.15 (1H, dd, J1 = 1.20 Hz, J2 = 1.20 Hz, thiophen
H4); 8.21 (1H, dd, J1 = 1.20 Hz, J2 = 1.20 Hz, thiophen
H5), Elemental Analysis: Found, %: C 54.88; H 2.89; S
11.32, Calculated, %: C 55.14; H 2.85; S 11.32.
4.2.6. 3-(2,6-Dichlorophenyl)-1-phenylprop-2-ene-1-one1f
Yield 90%, mp 84–85 C (EtOH), (Reference mp. 84–85 C,
Jun et al., 2007), UV (EtOH), kmax (loge: 207 (3.85), 288
(4.10), IR cm1 (cm1): 3084, 3024 (CH), 1668 (C‚O).
4.2.7. 3-(4-Methoxyphenyl)-1-[4-
(methylsulphonyl)phenyl]prop-2-ene-1-one 1g
Yield 82%, mp 159–161 C (EtOH) (Reference mp 165–
166 C, Yarishkin et al., 2008), UV (EtOH), kmax (loge): 205
(4.00), 249 (4.10), 353 (4.25), IR cm1 (cm1): 3009, 2972
(CH), 1658 (C‚O), 1288, 1145 (SO2).
4.2.8. 3-(3,4-Dimethoxyphenyl)-1-(thiophen-2-yl)prop-2-ene-1-
one1h
Yield 87%, mp 102–103 C (EtOH) (Reference mp 106 C,
Dos Santos et al., 2008), UV (EtOH), kmax (loge): 208 (4.15),
266 (4.20), 364 (4.24), IR cm1. (cm1): 3107, 3075 (CH),
1637 (C‚O).
4.2.9. 3-[4-(Dimethylamino)phenyl]-1-(thiophen-2-yl)prop-2-
ene-1-one1i
Yield 73%, mp 114–115 C (ethanol) (Reference mp 114 C,
Navarini et al., 2009), UV (EtOH), kmax (loge): 205 (4.10),
277 (4.18), 427 (4.20), IR cm1 (cm1): 3089, 2904 (CH),
1629 (C‚O).
4.3. General procedure for the preparation of 3,5-disubstituted-
4,5-dihydro-1H-pyrazole-1-carbothioamides 2a–i
2 mmol chalcone was heated in ethanol (10 ml). To that mix-
ture, the thiosemicarbazide (2.4 mmol) was added. Finally, a
solution of 5 mmol NaOH in 1 ml was added and reﬂuxed
on a water bath for 8–12 h. The progress of the reaction was
monitored by TLC. After completion of the reaction, the reac-
tion mixture was poured onto ice and the precipitate was ﬁl-
tered, dried and crystallized from suitable solvent.
4.3.1. 5-(4-Methoxyphenyl)-3-[4-(triﬂuoromethyl)phenyl]-4,5-
dihydro-1H-pyrazole-1-carbothioamide2a
C18H16F3N3OS (M.W.: 379.399), Yield 72%, mp 200–202 C
(EtOH), UV (EtOH), kmax (loge): 204 (4.00), 226 (4.05), 332
(4.12), IR cm1 (cm1): 3454, 3323 (NH), 1579 (C‚N), 1363Please cite this article in press as: Beyhan, N. et al., Synthesis an
chalcones. Arabian Journal of Chemistry (2013), http://dx.doi.org(C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.17 (1H, dd, HA, JAB = 18.13 Hz, JAX = 3.45 Hz);
3.72 (3H, s, –OCH3); 3.91 (1H, dd, HB, JBA = 18.14 Hz,
JBX = 11.45 Hz); 5.90 (1H, dd, HX, JXA = 3.44 Hz,
JXB = 11.45 Hz); 6.86 (2H, d, J= 8.74 Hz, 4-methoxyphenyl
H3, H5); 7.07 (2H, d, J= 8.71 Hz, 4-methoxyphenyl H2,
H6); 7.81 (2H, d, J= 8.32 Hz, 4-triﬂuoromethylphenyl H2,
H6); 8.03 (1H, bs, NH); 8.07-8.16 (2H, d, J= 8.16 Hz, 4-tri-
ﬂuoromethylphenyl H3, H5) 8.18 (1H, bs, NH), 13C NMR
(100 MHz), (DMSO-d6/TMS), d(ppm): 42.93 (pyrazole C4);
55.84 (OCH3); 63.54 (pyrazole C5); 115.00, 123.89 126.62,
126.75, 126.79, 127.93, 128.99, 131.14, 131.46, 136.20, 136.29,
159.68 (aromatic C ve CF3); 154.83 (pyrazole C3); 178.02
(C‚S), Elemental Analysis: Found, %: C 56.83; H 4.12; N
11.07; S 7.67, Calculated, %: C 56.98; H 4.25; N11.08; S
8.45, ES-MS: m/z 380.399 [MH]+.
4.3.2. 3-(5-Chlorothiophen-2-yl)-5-(2,6-dichlorophenyl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide 2b
C14H10Cl3N3S2 (M.W.: 390.738), Yield 45%, mp 256–257 C
(EtOH), UV (EtOH), kmax (loge): 203 (4.12), 248 (4.08), 347
(4.20), IR cm1 (cm1): 3437, 3250 (NH), 1585 (C‚N), 1371
(C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.17 (1H, dd, HA, JAB: 18.07 Hz, JAX: 7.70 Hz); 3.96 (1H,
dd, HB, JBA: 18.06 Hz, JBX: 12.97 Hz); 6.31 (1H, dd, HX, JXA:
7.68 Hz, JXB: 12.95 Hz); 7.22 (1H, d, J: 3.97 Hz, thiophen H3);
7.26 (1H, t, J1: 8.03 Hz, J2: 8.01 Hz, 2,6-dichlorophenyl H4);
7.35 (1H, d, J: 3.93 Hz, thiophen H4); 7.39 (1H, d, J: 7.21 Hz,
2,6-dichlorophenyl H3); 7.45 (1H, d, J: 7.33 Hz, 2,6-dichloro-
phenyl H5); 7.57 (1H, bs, NH); 8.03 (1H, bs, NH), 13C NMR
(100 MHz), (DMSO-d6/TMS), d(ppm): 40.34 (pyrazole C4);
60.0 (pyrazole C5); 129.28, 129.73, 131.17, 131.68, 133.09,
133.91, 134.01, 136.21, 137.62 (aromatic C); 150.80 (pyrazole
C3); 177.10 (C‚S), Elemental Analysis: Found, %: C 43.12;
H 2.42; N 10.66; S 17.03, Calculated, %: C 43.03; H 2.58; N
10.75; S 16.41, ES-MS: m/z 390.738 [MH]+.
4.3.3. 3-(5-Bromothiophen-2-yl)-5-(2,6-dichlorophenyl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide 2c
C14H10BrCl2N3S2 (M.W.: 435.189), Yield 52%, mp 259–
260 C (EtOH), UV (EtOH), kmax (loge): 202 (4.10), 221
(4.09), 250 (4.00), 348 (4.25). IR cm1 (cm1): 3412, 3246
(NH), 1587 (C‚N), 1373(C‚S), 1H NMR (400 MHz,
DMSO-d6/TMS), d, ppm (J, Hz): 3.13 (1H, dd, HA,
JAB = 18.06 Hz, JAX = 7.68 Hz); 3.97 (1H, dd, HB,
JBA = 18.08 Hz, JBX = 13.02 Hz); 6.29 (1H, dd, HX,
JXA = 7.67 Hz, JXB = 13.01 Hz); 7.30 (3H, m, 2,6-dichloro-
phenyl H4 and thiophen H3, H4); 7.39 (1H, d, J= 7.99 Hz,
2,6-dichlorophenyl H3); 7.43 (1H, d, J= 7.97 Hz, 2,6-dichlo-
rophenyl H5); 7.55(1H, bs, NH); 8.00 (1H, bs, NH), 13C
NMR (100 MHz), (DMSO-d6/TMS), d(ppm): 60.49 (pyrazole
C5); 116.37, 129.15, 129.91, 130.59, 131.89, 132.16, 133.31,
135.59, 136.06, 137.02 (aromatic C); 149.98 (pyrazole C3);
176.19 (C‚S), Elemental Analysis: Found, %: C 38.06; H
2.34; N 8.43; S 14.89, Calculated, %: C 38.64; H 2.32; N
9.66; S 14.74, ES-MS: m/z 436.189 [MH]+.
4.3.4. 5-(2,6-Dichlorophenyl)-3-[4-(methylsulphonyl)phenyl]-
4,5-dihydro-1H-pyrazole-1-carbothioamide 2d
C17H15Cl2N3O2S2 (M.W.: 428.356), Yield 39%, mp 264–
265 C (EtOH), UV (EtOH), kmax (loge): 205 (4.16), 232d anticonvulsant activity of some 2-pyrazolines derived from
/10.1016/j.arabjc.2013.07.037
6 N. Beyhan et al.(4.06), 317 (4.11). IR cm1 (cm1): 3450, 3331 (NH), 1581
(C‚N), 1357 (C‚S), 1H NMR (400 MHz, DMSO-d6/TMS),
d, ppm (J, Hz): 3.22 (1H, dd, HA, JAB = 18.36 Hz,
JAX = 7.43 Hz); 3.25 (3H, s, –SO2CH3); 3.98 (1H, dd, HB,
JBA = 18.36 Hz, JBX = 12.90 Hz); 6.32 (1H, dd, HX,
JXA = 7.81 Hz, JXB = 13.28 Hz); 7.23 (1H, t, J1 = 7.82 Hz,
J2 = 8.20 Hz, 2,6-dichlorophenyl H4); 7.36 (1H, d,
J= 8.21 Hz, 2,6-dichlorophenyl H3); 7.43 (1H, d,
J= 8.21 Hz, 2,6-dichlorophenyl H5); 7.97 (2H, d,
J= 8.60 Hz, 4-methylsulphonylphenyl H2, H6); 8.12 (2H, d,
J= 8.20 Hz, 4-methyl sulphonylphenyl H3, H5); 8.0 (1H, bs,
NH); 8.14 (1H, bs, NH), 13C NMR (100 MHz), (DMSO-d6/
TMS), d(ppm): 44.02 (SO2CH3); 60.72 (pyrazole C5); 127.96,
128.31, 129.15, 129.91, 130.59, 133.40, 135.61, 136.29, 137.12,
142.39 (aromatic C); 153.19 (pyrazole C3); 176.85 (C‚S), Ele-
mental Analysis: Found, %: C 47.76; H 3.72; N 9.68; S 15.09,
Calculated, %: C 47.67; H 3.53; N 9.81; S 14.97, ES-MS: m/z
429.356 [MH]+.
4.3.6. 5-(2,6-Dichlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-
1H-pyrazole-1-carbothioamide 2e
C14H11Cl2N3S2 (M.W.: 356.293), Yield 42%, mp 202–203 C
(EtOH), UV (EtOH), kmax (loge): 204 (4.10), 224 (4.22), 338
(4.00), IR cm1 (cm1): 3410, 3248 (N–H), 1589 (C‚N),
1361 (C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm
(J, Hz): 3.20 (1H, dd, HA, JAB = 18.40 Hz, JAX = 7.60 Hz);
4.00 (1H, dd, HB, JBA = 18.40 Hz, JBX = 12.80 Hz); 6.30
(1H, dd, HX, JXA = 7.60 Hz, JXB = 12.80 Hz); 7.17 (1H, dd,
J1 = 3.60 Hz, J2 = 3.60 Hz, thiophen H4); 7.24-7.46 (3H, m,
2,6-dichlorophenyl H-3, H4, H5); 7.47-7.52 (2H, d, J:
3.20 Hz, thiophen H3 ve NH); 7.78 (1H, d, J= 4.80 Hz, thio-
phen H5); 8.00 (1H, bs, NH), 13C NMR (100 MHz), (DMSO-
d6/TMS), d(ppm): 40.93 (pyrazole C4); 60.34 (pyrazole C5);
128.76, 129.14, 129.85, 130.58, 130.75, 131.35, 133.30, 134.26,
135.61, 137.14 (aromatic C); 150.92 (pyrazole C3); 176.10
(C‚S), Elemental Analysis: Found, %: C 47.52; H 3.08; N
10.88; S 18.38, Calculated, %: C 47.19; H 3.11; N 11.79; S
18.00, ES-MS: m/z 357.293 [MH]+.
4.3.7. 5-(2,6-Dichlorophenyl)-3-phenyl-4,5-dihydro-1H-
pyrazole-1-carbothioamide2f
C16H13Cl2N3S (M.W.: 350.265), Yield 43%, mp 209–210 C
(EtOH), UV (EtOH), kmax (loge): 203 (4.05), 222 (4.15), 321
(4.18), IR cm1 (cm1): 3435, 3232 (NH), 1587 (C‚N), 1348
(C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.20 (1H, dd, HA, JAB = 18.36 Hz, JAX = 7.81 Hz); 3.97
(1H, dd, HB, JBA = 17.97 Hz, JBX = 12.90 Hz); 6.30 (1H, dd,
HX, JXA = 7.81 Hz, JXB = 12.90 Hz); 7.24–7.46 (3H, m, 2,6-
dichlorophenyl H3, H4, H5); 7.46–7.51 (3H, m, phenyl H3,
H4, H5); 7.82 (1H, bs, NH); 7.85-7.90 (2H, m, phenyl H2,
H6); 8.10 (1H, bs, NH), 13C NMR (100 MHz), (DMSO-d6/
TMS), d(ppm): 60.34 (pyrazole C5); 127.68, 129.11, 129.36,
129.79, 130.56, 131.10, 131.46, 133.37, 135.64, 137.31 (aromatic
C); 154.77 (pyrazole C3); 176.48 (C‚S), Elemental Analysis:
Found, %: C 54.78; H 3.87; N 11.94; S 9.11, Calculated, %: C
54.86; H 3.74; N 12.00; S 9.15, ES-MS: m/z 351.265 [MH]+.
4.3.8. 5-(4-Methoxyphenyl)-3-[4-(methylsulphonyl)phenyl]-
4,5-dihydro-1H-pyrazole-1-carbothioamide2g
C18H19N3O3S2 (M.W.: 389.491), Yield 39%, mp 226–227 C
(EtOH), UV (EtOH), kmax (loge): 201 (4.10), 226 (4.08) 334Please cite this article in press as: Beyhan, N. et al., Synthesis an
chalcones. Arabian Journal of Chemistry (2013), http://dx.doi.org(4.12), IR cm1 (cm1): 3462, 3346 (NH), 1583 (C‚N), 1400
(C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.17 (1H, dd, HA, JAB = 18.03 Hz, JAX = 7.56 Hz);
3.25 (3H, s, –SO2CH3); 3.72 (3H, s, –OCH3); 3.93 (1H, dd,
HB, JBA = 18.04 Hz, JBX = 11.45 Hz); 5.90 (1H, dd, HX,
JXA = 8.01 Hz, JXB = 11.46 Hz); 6.87 (2H, d, J= 8.75 Hz,
4-methoxyphenyl H3, H5); 7.07 (2H, d, J= 8.72 Hz, 4-
methoxyphenyl H2, H6); 7.98 (2H, d, J= 8.64 Hz, 4-methyl-
sulphonylphenyl H2, H6); 8.15 (2H, d, J= 8.53 Hz, 4-methyl-
sulphonylphenyl H3, H5); 8.08 (1H, bs, NH); 8.11 (1H, bs,
NH), 13C NMR (100 MHz), (DMSO-d6/TMS), d(ppm):
42.86 (pyrazole C4); 44.02 (SO2CH3); 55.72 (OCH3); 63.45
(pyrazole C5); 110.00, 114.52, 127.36, 127.93, 128.44, 135.56,
136.47, 142.40, 158.92 (aromatic C); 153.91 (pyrazole C3);
177.14 (C‚S), Elemental Analysis: Found,%: C 55.20; H
4.90; N 11.11; S 16.74, Calculated,%: C 55.51; H 4.92; N
10.79; S 16.47, ES-MS: m/z 390.491 [MH]+.
4.3.8. 5-(3,4-Dimethoxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-
1H-pyrazole-1-carbothioamide 2h
C16H17N3O2S2 (M.W.: 347.455), Yield 32%. mp 183–184 C
(EtOH), UV (EtOH), kmax (loge): 204 (4.12), 222 (4.20), 277
(4.09), 341 (4.10), IR cm1 (cm1): 3444, 3323 (NH), 1573
(C‚N), 1348 (C‚S), 1H NMR (400 MHz, DMSO-d6/TMS),
d, ppm (J, Hz): 3.12 (1H, dd, HA, JAB = 17.75 Hz,
JAX = 3.07 Hz); 3.71 (6H, s, –OCH3); 3.87 (1H, dd, HB,
JBA = 17.75 Hz, JBX = 11.20 Hz); 5.85 (1H, dd, HX,
JXA = 3.01 Hz, JXB = 11.16 Hz); 6.58 (1H, d, J= 8.29 Hz,
3,4-dimethoxyphenyl H5); 6.79 (1H, s, 3,4-dimethoxyphenyl
H2); 6.88 (1H, d, J= 8.31 Hz, 3,4-dimethoxyphenyl H6);
7.15 (1H, dd, J1 = 4.82 Hz, J2 = 3.84 Hz, thiophen H4);
7.48 (1H, d, J= 3.49 Hz, thiophen H3); 7.59 (1H, bs, NH);
7.78 (1H, d, J= 4.95 Hz, thiophen H5); 7.96 (1H, bs, NH),
13C NMR (100 MHz), (DMSO-d6/TMS), d(ppm): 43.87 (pyra-
zole C4); 56.13, 56.18 (3-OCH3 and 4-OCH3); 63.30 (pyrazole
C5); 110.29, 112.52, 117.53, 128.80, 131.02, 131.74, 134.55,
135.80, 148.47, 149.35 (aromatic C); 151.86 (pyrazole C3);
176.48 (C‚S), Elemental Analysis: Found, %: C 54.77; H
5.07; N 11.82; S 18.21, Calculated, %: C 55.31; H 4.93; N
12.09; S 18.46, ES-MS: m/z 348.455 [MH]+.
4.3.19. 5-[4-(Dimethylamino)phenyl]-3-(thiophen-2-yl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide2i
C16H18N4S2 (M.W.: 330.470), Yield 39%, mp 222–224 C
(EtOH), UV (EtOH), kmax (loge: 207 (4.10), 262 (4.09), 341
(4.20), IR cm1 (cm1): 3439, 3240 (NH), 1563 (C‚N), 1366
(C‚S), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 2.85 (6H, s, N(CH3)2); 3.10 (1H, dd, HA, JAB = 17.65 Hz,
JAX = 2.98 Hz); 3.86 (1H, dd, HB, JBA = 17.65 Hz,
JBX = 11.08 Hz); 5.84 (1H, dd, HX, JXA = 2.90 Hz,
JXB = 11.07 Hz); 6.67 (2H, d, J= 8.81 Hz, 4-dimethylamin-
ophenyl H3, H5); 6.94 (2H, d, J= 8.75 Hz, 4-dimethylamin-
ophenyl H2, H6); 7.15 (1H, dd, J1 = 3.65 Hz, J2 = 3.65 Hz,
thiophen H4); 7.41-7.53 (2H, d, J= 3.65 Hz, thiophen H3
and NH); 7.76 (1H, d, J= 5.04 Hz, thiophen H5); 7.90 (1H,
bs, NH), 13C NMR (100 MHz), (DMSO-d6/TMS), d(ppm):
43.86 (pyrazole C4); 63.20 (pyrazole C5); 113.10, 126.84,
128.84, 130.97, 131.68, 134.70, 150.30 (aromatic C); 151.93
(pyrazole C3); 176.29 (C‚S), Elemental Analysis: Found,%:
C 58.18; H 5.47; N 16.82; S 19.38, Calculated,%: C 58.15; H
5.49; N 16.95; S 19.4,. ES-MS: m/z 331.71 [MH]+.d anticonvulsant activity of some 2-pyrazolines derived from
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Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones 74.4. General synthesis methods of N,3,5-trisubstituted-4,5-
dihydro-1H-pyrazole-1-carboxamides 3a-e
5 mmol 4-chlorophenylisocyanate was dissolved in diethyl ether.
To the stirred mixture, 5 mmol hydrazine was added dropwise
and stirred for 15 min. The obtained 4-chlorophenylsemicarbaz-
ideswere ﬁltered, dried andwashedwith petrol ether. 2 mmol chal-
cone was dissolved in ethanol (10 ml) and then, the semicarbazide
was added. Finally, a solution of 5 mmolNaOH in 1 ml water was
added. After the completion of the reaction by TLC, the reaction
mixture was poured onto ice and the precipitate was ﬁltered,
dried and crystallized from suitable solvent.
4.4.1. N-(4-chlorophenyl)semicarbazide
Yield 98%, mp 275–277 C (EtOH), UV (EtOH), kmax (loge):
204 (3.98), 247 (4.10), IR cm1. (cm1): 3330, 3292, 3218, 3098,
2980, 2924, 1667, 1592, 1530 1491, 1455, 1405, 1093.
4.4.2. N-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-3-phenyl-4,5-
dihydro-1H-pyrazole-1-carboxamide3a
C22H16Cl3N3O (M.W.: 445.740), Yield 35%, mp 183–185 C
(EtOH), UV (EtOH), kmax (loge): 204 (4.00), 225 (4.12), 269
(4.22), 323 (4.25), IR cm1 (cm1): 3382 (NH), 1678 (C‚O), 1579
(C‚N), 1H NMR (400MHz, DMSO-d6/TMS), d, ppm (J, Hz):
3.22 (1H, dd, HA, JAB=17.94 Hz, JAX=5.50 Hz); 3.72 (3H, s,
OCH3); 3.90 (1H, dd, HB, JBA=17.94 Hz, JBX=12.04 Hz); 5.50
(1H, dd, HX, JXA=5.50 Hz, JXB=12.01 Hz); 7.19–7.66 (12H,
m, Ar–H) 9.19 (1H, s, NH), 13C NMR (100MHz), (DMSO-d6/
TMS), d(ppm): 42.55 (pyrazole C4); 60.73 (pyrazole C5); 130.11,
130.43, 131.32, 135.53, 135.97, 137.57, 151.14 (aromatic C); 151.83
(pyrazole C3); 159.16 (CC‚O), Elemental Analysis: Found, %:
C 59.36; H 3.55; N 9.62, Calculated, %: C 59.41; H 3.63; N
9.45, ES-MS: m/z 351.265 [MH]+.
4.4.3. N-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-3-(4-methylsul-
fonylphenyl)- 4,5-dihydro-1H-pyrazole-1-carboxamide 3b
C23H18Cl3N3OS (M.W.: 522.832), Yield 53%, mp 237–239 C
(EtOH), UV (EtOH), kmax (loge): 205 (4.10), 232 (4.22), 317
(4.15), IR cm1 (cm1): 3440, 3325 (NH), 1695 (C‚O), 1595
(C‚N), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.22 (1H, dd, HA, JAB = 18.36 Hz, JAX = 7.43 Hz); 3.25
(3H, s, –SO2CH3); 3.98 (1H, dd, HB, JBA = 18.36 Hz,
JBX = 12.90 Hz); 6.32 (1H, dd, HX, JXA = 7.81 Hz,
JXB = 13.28 Hz); 7.23 (1H, t, J1 = 7.82 Hz, J2 = 8.20 Hz,
2,6-dichlorophenyl H4); 7.30 (2H, d, J= 8.86 Hz, 4-chloro-
phenyl H3, H5); 7.39 (1H, d, J= 7.99 Hz, 2,6-dichlorophenyl
H3); 7.43 (1H, d, J= 7.97 Hz, 2,6-dichlorophenyl H5); 7.66
(2H, d, J= 8.91 Hz, 4-chlorophenyl H2, H6); 7.97 (2H, d,
J= 8.60 Hz, 4-methylsulphonylphenyl H2, H6); 8.12 (2H, d,
J= 8.20 Hz, 4-methylsulphonylphenyl H3, H5); 9.15 (1H, s,
NH), 13C NMR (100 MHz), (DMSO-d6/TMS), d(ppm): 44.02
(SO2CH3); 60.72 (pyrazole C5); 127.96, 128.31, 129.15, 129.91,
130.59, 133.40, 135.61, 136.29, 137.12, 142.39 (aromatic C);
153.19 (pyrazole C3); 161.82 (C‚O), Elemental Analysis:
Found, %: C 52.10; H 3.42; N 8.60; S 6.50, Calculated, %: C
52.84; H 3.47; N 8.04; S 6.13, ES-MS: m/z 523.832 [M+ H].
4.4.4. N-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-3-(thiophen-
2-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide 3c
C20H14Cl3N3OS (M.W.: 450.769), Yield 45%, mp 166–168 C
(EtOH), UV (EtOH), kmax (loge): 204 (4.10), 224 (4.12), 338Please cite this article in press as: Beyhan, N. et al., Synthesis an
chalcones. Arabian Journal of Chemistry (2013), http://dx.doi.org(4.20), IR cm1 (cm1): 3360, 3248 (NH), 1670 (C‚O), 1590
(C‚N), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.20 (1H, dd, HA, JAB = 18.40 Hz, JAX = 7.60 Hz);
4.00 (1H, dd, HB, JBA = 18.40 Hz, JBX = 12.80 Hz); 6.30
(1H, dd, HX, JXA = 7.60 Hz, JXB = 12.80 Hz); 7.17 (1H, dd,
J1 = 3.60 Hz, J2 = 3.60 Hz, thiophen H4); 7.24–7.46 (5H, m,
2,6-dichlorophenyl H-3, H4, H5 ve 4-chlorophenyl H3, H5);
7.47–7.52 (1H, d, J= 3.20 Hz, thiophen H3); 7.62 (2H, d,
J= 8.87 Hz, 4-chlorophenyl H2, H6); 7.78 (1H, d,
J= 4.80 Hz, thiophen H5); 9.25 (1H, s, NH),13C NMR
(100 MHz), (DMSO-d6/TMS), d(ppm): 40.93 (pyrazole C4);
60.34 (pyrazole C5); 128.76, 129.14, 129.85, 130.58, 130.75,
131.35, 133.30, 134.26, 135.61, 137.14 (aromatic C); 150.92
(pyrazole C3); 166.10 (C‚O): Elemental Analysis: Found,
%: C 47.52; H 3.08; N 10.88; S 18.38, Calculated, %: C
53.29; H 3.13; N 9.32; S 7.11, ES-MS: m/z 451.768 [MH]+.
4.4.5. 3-(5-Bromothiophen-2-yl)-N-(4-chlorophenyl)-5-(2,6-
dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide 3d
C20H13BrCl3N3OS (M.W.: 529.665), Yield 53%, mp 198–
200 C (EtOH), UV (EtOH), kmax (loge): 202 (4.14), 221
(4.10), 250 (4.20), 348 (4.10), IR cm1 (cm1): 3400, 3250
(NH), 1686 (C‚O), 1580 (C‚N), 1H NMR (400 MHz,
DMSO-d6/TMS), d, ppm (J, Hz): 3.13 (1H, dd, HA,
JAB = 18.06 Hz, JAX = 7.68 Hz); 3.97 (1H, dd, HB,
JBA = 18.08 Hz, JBX = 13.02 Hz); 6.29 (1H, dd, HX,
JXA = 7.67 Hz, JXB = 13.01 Hz); 7.30 (3H, m, 2,6-dichloro-
phenyl H4 ve thiophen H3, H4); 7.39 (1H, d, J= 7.99 Hz,
2,6-dichlorophenyl H3); 7.43 (1H, d, J: 7.97 Hz, 2,6-dichloro-
phenyl H5); 9.05 (1H, s, NH), 13C NMR (100 MHz),
(DMSO-d6/TMS), d(ppm): 60.49 (pyrazole C5); 116.37,
129.15, 129.91, 130.59, 131.89, 132.16, 133.31, 135.59, 136.06,
137.02 (aromatic C); 149.98 (pyrazole C3); 164.18 (C‚O), Ele-
mental Analysis: Found, %: C 45.50; H 2.45; N 7.90; S 6.00,
Calculated, %: C 45.35; H 2.47; N 7.93; S 6.05, ES-MS: m/z
530.665 [MH]+.4.4.6. N-(4-chlorophenyl)-5-(2,6-dichlorophenyl)-3-(5-
chlorothiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide
3e
C20H13Cl4N3OS (M.W.: 485.214), Yield 45%, mp 256–257 C
(EtOH), UV (EtOH), kmax (loge): 203 (4.05), 248 (4.15), 347
(4.20), IR cm1 (cm1): 3440, 3220 (NH), 1690 (C‚O), 1580
(C‚N), 1H NMR (400 MHz, DMSO-d6/TMS), d, ppm (J,
Hz): 3.17 (1H, dd, HA, JAB = 18.07 Hz, JAX = 7.70 Hz);
3.96 (1H, dd, HB, JBA = 18.06 Hz, JBX = 12.97 Hz); 6.31
(1H, dd, HX, JXA = 7.68 Hz, JXB = 12.95 Hz); 7.22 (1H, d,
J= 3.97 Hz, thiophen H3); 7.26 (1H, t, J1 = 8.03 Hz,
J2 = 8.01 Hz, 2,6-dichlorophenyl H4); 7.30 (2H, d,
J= 8.80 Hz, 4-chlorophenyl H3, H5); 7.35 (1H, d,
J= 3.93 Hz, thiophen H4); 7.39 (1H, d, J= 7.21 Hz, 2,6-
dichlorophenyl H3); 7.45 (1H, d, J= 7.33 Hz, 2,6-dichloro-
phenyl H5); 7.66 (2H, d, J= 8.80 Hz, 4-chlorophenyl H2,
H6); 9.10 (1H, s, NH), 13C NMR (100 MHz), (DMSO-d6/
TMS), d(ppm): 40.34 (pyrazole C4); 60.0 (pyrazole C5);
129.28, 129.73, 131.17, 131.68, 133.09, 133.91, 134.01, 136.21,
137.62 (aromatic C); 151.20 (pyrazole C3); 164.20 (C‚O), Ele-
mental Analysis: Found, %: C 49.48; H 2.68; N 8.64; S 6.58,
Calculated, %: C, 49.51; H, 2.70; N, 8.66; S, 6.61, ES-MS:
m/z 486.214 [MH]+.d anticonvulsant activity of some 2-pyrazolines derived from
/10.1016/j.arabjc.2013.07.037
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Male and female adult BALB/c mice weighing 20–30 g were
used. The animals were housed in colongy cages, under
standard laboratory conditions on a 12-h light–dark cycle
(8 a.m.–8 p.m.), with free access to food and tap water.
Room temperature and relative humidity were maintained
at 22 ± 1 C and 60%, respectively. All tests were con-
ducted during the light phase of day. After the adaption
period of 2 days, experimental groups were chosen ran-
domly. Each mouse was used only once. The experimental
protocols were approved by the Animal Care and
Use Committee of Marmara University (16.04.2009–
02.04.2009).
4.5.1. Anticonvulsant activity
The anticonvulsant activities of the new compounds were
determined by using PTZ (Sigma) and MES tests. These ro-
dent models are widely used as standard methods for predict-
ing protection against generalized absence and tonic–clonic
seizures in humans (Borowicz et al., 2010). All synthesized
compounds were suspended in 0.5% methyl cellulose and
administered at a dose of 50 mg/kg 30 min prior the tests.
Effective dose 50 (ED50) value for PTZ (60 mg/kg) and convul-
sive current 50 (CC50) of animals and the 95% ﬁducial limits
were calculated by the method of Litchﬁeld and Wilcoxon
(1949).
4.5.2. PTZ test
The animals of the control group received same volume of
saline in PTZ test. 30 min after the administration of the test
compounds, mice were injected intraperitoneally with 60 mg/
kg PTZ and observed for 15 min. Motor responses were
graded from 0 to 5 according to the scale of Racine, where
grade 1: no movements, grade 2: head twitching and myo-
clonic jerks (MKJ), grade 3: clonic forelimb convulsions,
grade 4: three plus change in posture, and grade 5: falling
back and generalized convulsions with tonic extension (Ra-
cine, 1972).
4.5.3. MES test
MES test was performed 30 min after the administration of
the test compounds. Electroshocks were evoked through a
current transmitter producing square waves (Ari Technical
ECT unit). In the MES test, seizures were elicited with a
60-Hz alternating current of 25 mA intensity in BALB/c
mice. The current was applied via ear clip electrodes for
450 ms. During the shock, electrodes were attached to each
animal’s ear and the animals lay on their backs, while their
tails are ﬁxed. Thus, observation of the tonic and clonic
convulsions appearing during the seizure was ensured (Krall
et al., 1978).
4.5.4. Statistics
Statistical analyses were evaluated by using analysis of vari-
ance (ANOVA) followed by unpaired Student’s t-test using
Prism 3.0 (GraphPad Software, San Diego, CA, USA). ED50
values, as well as their statistical evaluation, were estimated
by computer probit analysis, according to Litchﬁeld and Wil-
coxon (1949).Please cite this article in press as: Beyhan, N. et al., Synthesis an
chalcones. Arabian Journal of Chemistry (2013), http://dx.doi.orgAcknowledgement
This study was supported by the Marmara University Scien-
tiﬁc Research Projects Commission (BAPKO, Project number
SAG-A -040609-0140).
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